Journal of Clinical Pharmacy and Therapeutics

A total of 105 recurrent spontaneous abortion (RSA) patients who received tumour necrosis factor inhibitor (TNFi) + intravenous immunoglobin (IVIG) + Heparin (enoxaparin) (n = 48) or IVIG+Heparin (enoxaparin) (n = 57) were retrospectively included in this two-centre cohort study. Live birth rate was increased in the TNFi+IVIG+Heparin group compared to the IVIG+Heparin group (72.9% vs. 52.6%). After adjustment by the multivariate logistic regression model, TNFi+IVIG+Heparin was also superior to IVIG+Heparin regarding the increased live birth rate. However, other obstetric outcomes and adverse event incidence were of no difference between TNFi+IVIG+Heparin and IVIG+Heparin group. Interestingly, it was observed that younger age and less number of previous miscarriages related to a higher live birth rate in the TNFi+IVIG+Heparin group but not in the IVIG+Heparin group.

Guide to XR-NTX Discussion for Patients on Therapeutic Anticoagulation.

The current study aimed to comprehensively evaluate the potential effects of mulberry consumption on cardio metabolic risk factors in adults. The current systematic review and meta-analysis revealed that incorporating mulberry into the diet may favourably affect several cardio metabolic risk factors. Consumption > 300 mg/day of mulberry exhibited a favourable effect on serum high-density lipoprotein levels (HDL-C).

This study aimed to investigate the treatment efficacy and safety of camrelizumab (programmed cell death protein-1 (PD-1) inhibitor) plus apatinib as third-line or above therapy in metastatic colorectal cancer (mCRC) patients. Totally, 64 unresectable mCRC patients receiving camrelizumab plus apatinib (N = 31) and apatinib (N = 33) were retrospectively enrolled. It was found that disease control rate and objective response rate (ORR) were increased in camrelizumab plus apatinib group compared to apatinib group, but ORR did not achieve statistical significance. Besides, the median (95% confidence interval [CI]) progressive-free survival (PFS) and overall survival (OS) were 6.9 (3.7–10.1) and 11.5 (7.7–15.3) months in camrelizumab plus apatinib group, as well as 3.6 (1.7–5.5) and 6.7 (5.0–8.4) months in apatinib group. Additionally, PFS and OS were prolonged in camrelizumab plus apatinib group compared with apatinib group. The incidence of adverse events did not differ between groups. Conclusively, camrelizumab (PD-1 inhibitor) plus apatinib achieves a better treatment efficacy than apatinib as third-line or above therapy with a good safety profile in mCRC patients.

Daratumumab and bortezomib-containing regimen induce severe lung injury in a patient with preexisting interstitial lung disease

The study collected 108 blood specimens and60 sputum specimens from 12 enrolled patients Subsequently, these specimens were assayedfor tigecycline drug concentrations by high-performance liquid chromatography (HPLC).The relevant pharmacokinetic (PK) parameters were estimated by the non-compartmental model usingWinNonlin software. And Crystal Ball software was used to carry out Monte Carlosimulations. The results of this study showed that the mean lung penetrationrate calculated by the sputum was 127.27% and the probability of targetattainments (PTAs) in plasma and sputum ≥90.00% when the minimal inhibit concentration (MIC) ≤ 4 mg/L. Hence, the findings of PK/PD parameters of high-dosetigecycline in patients with HAP caused by MDRB demonstrated that high-dosetigecycline could achieve better antimicrobial effects when the MIC was ≤4 mg/L.

AVA® is a new electromechanical injection device for self-injecting certolizumab pegol (CZP). Thirty four patients were included (28 women) RA 11, PsA 10 and axial axSpA 13. Patients reported >90% adherence assessed with AVA® injection log and the full dose of CZP was injected on all patients with AVA® device. No safety findings related to AVA® CZP administration were identified. AVA® device is an advantageous delivery option for CZP. This study provides further evidence to support that AVA® device is a valid method for switching CZP from syringe or pen with highly preference in patients with RA, PsA and axSpa.

Posaconazole is a second-generation triazole antifungal agent with a broad antibacterial spectrum, strong antifungal activity, high safety tolerability and cost effectiveness compared to other azole antifungal agents. The literature on posaconazole shows an increasing trend year on year. However, the pharmacokinetic process of the drug is highly individual and its blood concentration is influenced by various factors such as the drug, the patient and the food, resulting in a failure to achieve preventive or therapeutic effects. In this paper, we present a review of the individualized therapy of posaconazole from therapeutic drug monitoring, population pharmacokinetics and Monte Carlo simulation. This review will provide a reference for the rational use of posaconazole and provide theoretical support for further individualized treatment studies.

Our study was of potential clinical significance to provide the real-world evidence that tirofiban exhibited a high safety profile and significantly improved the prognosis of patients with acute ischemic stroke (AIS) and early neurological deterioration (END) who missed the intravenous thrombolysis time window.

This open-label feasibility RCT aims to compare clinical outcomes achieved with Bayesian-guided AUC0-24h/MIC to trough level monitoring of vancomycin. Results demonstrated that it would be feasible to conduct a properly sized RCT comparing these vancomycin monitoring methods. Although exploratory, this trial also showed a tendency towards reduced incidence of nephrotoxicity and an increased proportion of dosages at therapeutic targets with Bayesian monitoring.

Present study represents significant anti-arthritis rheumatoid effects of G-Rup® syrup G-Rup® syrup (100 mg/ml ginger extract plus 150 mg/ml honey) in patients. Treatment with G-Rup® syrup could significantly lower the VAS score (p < 0.001) whereas improving WOMAC total score (p < 0.001) and pain (p < 0.001), physical functioning (p < 0.001), and stiffness sub-scores (p = 0.006) compared to the placebo receiving group.